Atea Pharmaceuticals, Inc. filed a Form 8-K with the U.S. Securities and Exchange Commission (SEC) at 12:30 UTC on Monday, 9 November 2026. The filing reports Item 1.01, Entry into a Material Definitive Agreement; Item 2.03, Creation of a Direct Financial Obligation.
A Form 8-K is the report U.S. public companies file to tell investors about significant events between their regular quarterly and annual reports. Each item in the form covers one type of event.
The filing also lists Item 9.01, Financial Statements and Exhibits.
Source: U.S. Securities and Exchange Commission (EDGAR) filing